{"record_type":"pith_number_record","schema_url":"https://pith.science/schemas/pith-number/v1.json","pith_number":"pith:2014:WLSSRIBTLIMQ6O6WALLEHERQ2V","short_pith_number":"pith:WLSSRIBT","schema_version":"1.0","canonical_sha256":"b2e528a0335a190f3bd602d6439230d5552bbbb97022681427ed076ce5268d59","source":{"kind":"arxiv","id":"1402.2550","version":1},"attestation_state":"computed","paper":{"title":"A New Approach to Designing Phase I-II Cancer Trials for Cytotoxic Chemotherapies","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":["stat.AP"],"primary_cat":"stat.ME","authors_text":"Balasubramanian Narasimhan, Jay Bartroff, Tze Leung Lai","submitted_at":"2014-02-11T16:27:30Z","abstract_excerpt":"Recently there has been much work on early phase cancer designs that incorporate both toxicity and efficacy data, called Phase I-II designs because they combine elements of both phases. However, they do not explicitly address the Phase II hypothesis test of $H_0: p\\le p_0$, where $p$ is the probability of efficacy at the estimated maximum tolerated dose (MTD) $\\widehat{\\eta}$ from Phase I and $p_0$ is the baseline efficacy rate. Standard practice for Phase II remains to treat $p$ as a fixed, unknown parameter and to use Simon's 2-stage design with all patients dosed at $\\widehat{\\eta}$. We pro"},"verification_status":{"content_addressed":true,"pith_receipt":true,"author_attested":false,"weak_author_claims":0,"strong_author_claims":0,"externally_anchored":false,"storage_verified":false,"citation_signatures":0,"replication_records":0,"graph_snapshot":true,"references_resolved":false,"formal_links_present":false},"canonical_record":{"source":{"id":"1402.2550","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.ME","submitted_at":"2014-02-11T16:27:30Z","cross_cats_sorted":["stat.AP"],"title_canon_sha256":"123477e017350a28f6626e82bf1e80b2496f24f00f117a62d3bef709cd41677c","abstract_canon_sha256":"5718d4601c598c1aecd68fcee4fe4184938a99995b85619a42beac5b51ea13f8"},"schema_version":"1.0"},"receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-18T02:59:19.337298Z","signature_b64":"vzc4LeMSl4tvDlqwcZUEr54x2DaSa3u2ou7NqoO44UzYETnUHoaKK5WB1B2kRRCLihFRrvxzab/AnQAMjRJlAA==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"b2e528a0335a190f3bd602d6439230d5552bbbb97022681427ed076ce5268d59","last_reissued_at":"2026-05-18T02:59:19.336472Z","signature_status":"signed_v1","first_computed_at":"2026-05-18T02:59:19.336472Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"graph_snapshot":{"paper":{"title":"A New Approach to Designing Phase I-II Cancer Trials for Cytotoxic Chemotherapies","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":["stat.AP"],"primary_cat":"stat.ME","authors_text":"Balasubramanian Narasimhan, Jay Bartroff, Tze Leung Lai","submitted_at":"2014-02-11T16:27:30Z","abstract_excerpt":"Recently there has been much work on early phase cancer designs that incorporate both toxicity and efficacy data, called Phase I-II designs because they combine elements of both phases. However, they do not explicitly address the Phase II hypothesis test of $H_0: p\\le p_0$, where $p$ is the probability of efficacy at the estimated maximum tolerated dose (MTD) $\\widehat{\\eta}$ from Phase I and $p_0$ is the baseline efficacy rate. Standard practice for Phase II remains to treat $p$ as a fixed, unknown parameter and to use Simon's 2-stage design with all patients dosed at $\\widehat{\\eta}$. We pro"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1402.2550","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"aliases":[{"alias_kind":"arxiv","alias_value":"1402.2550","created_at":"2026-05-18T02:59:19.336595+00:00"},{"alias_kind":"arxiv_version","alias_value":"1402.2550v1","created_at":"2026-05-18T02:59:19.336595+00:00"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1402.2550","created_at":"2026-05-18T02:59:19.336595+00:00"},{"alias_kind":"pith_short_12","alias_value":"WLSSRIBTLIMQ","created_at":"2026-05-18T12:28:54.890064+00:00"},{"alias_kind":"pith_short_16","alias_value":"WLSSRIBTLIMQ6O6W","created_at":"2026-05-18T12:28:54.890064+00:00"},{"alias_kind":"pith_short_8","alias_value":"WLSSRIBT","created_at":"2026-05-18T12:28:54.890064+00:00"}],"events":[],"event_summary":{},"paper_claims":[],"inbound_citations":{"count":0,"internal_anchor_count":0,"sample":[]},"formal_canon":{"evidence_count":0,"sample":[],"anchors":[]},"links":{"html":"https://pith.science/pith/WLSSRIBTLIMQ6O6WALLEHERQ2V","json":"https://pith.science/pith/WLSSRIBTLIMQ6O6WALLEHERQ2V.json","graph_json":"https://pith.science/api/pith-number/WLSSRIBTLIMQ6O6WALLEHERQ2V/graph.json","events_json":"https://pith.science/api/pith-number/WLSSRIBTLIMQ6O6WALLEHERQ2V/events.json","paper":"https://pith.science/paper/WLSSRIBT"},"agent_actions":{"view_html":"https://pith.science/pith/WLSSRIBTLIMQ6O6WALLEHERQ2V","download_json":"https://pith.science/pith/WLSSRIBTLIMQ6O6WALLEHERQ2V.json","view_paper":"https://pith.science/paper/WLSSRIBT","resolve_alias":"https://pith.science/api/pith-number/resolve?arxiv=1402.2550&json=true","fetch_graph":"https://pith.science/api/pith-number/WLSSRIBTLIMQ6O6WALLEHERQ2V/graph.json","fetch_events":"https://pith.science/api/pith-number/WLSSRIBTLIMQ6O6WALLEHERQ2V/events.json","actions":{"anchor_timestamp":"https://pith.science/pith/WLSSRIBTLIMQ6O6WALLEHERQ2V/action/timestamp_anchor","attest_storage":"https://pith.science/pith/WLSSRIBTLIMQ6O6WALLEHERQ2V/action/storage_attestation","attest_author":"https://pith.science/pith/WLSSRIBTLIMQ6O6WALLEHERQ2V/action/author_attestation","sign_citation":"https://pith.science/pith/WLSSRIBTLIMQ6O6WALLEHERQ2V/action/citation_signature","submit_replication":"https://pith.science/pith/WLSSRIBTLIMQ6O6WALLEHERQ2V/action/replication_record"}},"created_at":"2026-05-18T02:59:19.336595+00:00","updated_at":"2026-05-18T02:59:19.336595+00:00"}